Article - BioPharm International

ADVERTISEMENT

Article

Manufacturers Tackle Neglected Diseases

July 1, 2007

Now equipment makers are designing new systems that can be deployed rapidly, are less costly to build, and require less water and power to operate.

Vendor Notes: The Biovest AutovaxID: Enabling the Promise of Personalized Medicine

July 1, 2007

The AutovaxID is a self-contained, completely enclosed, fully automated hollow fiber bioreactor that permits rapid, efficient scale up of patient-derived cells. It is based on hollow fiber bioreactor technology and is an ideal system for high-density cell culture and the production of monoclonal antibodies or other therapeutic proteins.

From the Editor: Learning from the Diethylene Glycol Tragedies

July 1, 2007

Quality guidelines are only as good as their implementation.

Outsourcing Insights: Why European CMOs Are Coming to America

July 1, 2007

The BIO annual meeting in early May had an upbeat tone. Investment capital is flowing into the industry at high levels, resulting in strong demand for contract development services. The funding stream is particularly strong in the US, and that is attracting more European contract manufacturers (CMOs) eager to improve business development here.

Upstream Processing: Regulatory Considerations Regarding Quality Aspects of Monoclonal Antibodies

July 1, 2007

Operations Excellence: Optimizing Efficiency

July 1, 2007

In the April issue of BioPharm International, the article "BioPharmaceutical Operations Roadmap," provided a summary of the key industry gaps executives would like to close in the next 10 years. These goals came to my mind while I was attending Interphex this April in New York.

China Today: Next Steps Toward Globalization

July 1, 2007

Most Chinese biopharmaceuticals are relatively small and there are not enough of them to sustain a robust services sector.

cGMP Custom Manufacturing of Tomorrow's Medicines

June 2, 2007

Cobra Biomanufacturing is dedicated to designing robust processes that deliver high-quality preclinical and clinical biopharmaceutical products for its international life-sciences customers. From proteins and viruses to DNA and cells, Cobra offers a full range of biomanufacturing services and has established an enviable track record in cGMP manufacturing.

Very High Capacity Cation Exchange Resin

June 2, 2007

A new, very high capacity cation exchange resin* for process scale applications was developed by the researchers at Tosoh Corporation. This resin, with dynamic binding capacities approaching 145 mg/mL for IgG molecules, is the newest member of the Toyopearl product line.

ADVERTISEMENT

ADVERTISEMENT

Click here